| Empliciti (elotuzumab) / AbbVie, BMS |
NCT02541643: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma |
|
|
| No Longer Available | N/A | | US | Elotuzumab, BMS-901608 | Sundar Jagannath, Bristol-Myers Squibb | Multiple Myeloma | | | | |
NCT02976493: Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma |
|
|
| Completed | N/A | 500 | Japan | No Intervention | Bristol-Myers Squibb | Multiple Myeloma | 06/18 | 06/18 | | |
NCT03126617: Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma |
|
|
| No Longer Available | N/A | | NA | Elotuzumab, Empliciti, BMS-901608 | Bristol-Myers Squibb | Multiple Myeloma | | | | |
| Withdrawn | N/A | 0 | RoW | Non-Interventional | Bristol-Myers Squibb | Multiple Myeloma | 10/22 | 10/22 | | |
| No Longer Available | N/A | | NA | Elotuzumab in combination with Lenalidomide and Dexamethasone | Bristol-Myers Squibb | Multiple Myeloma | | | | |
NCT02856438: Early Patient Access Treatment Use Protocol CA204-220 |
|
|
| No Longer Available | N/A | | Japan | Elotuzumab, BMS-901608, Lenalidomide, Dexamethasone | Bristol-Myers Squibb, AbbVie | Multiple Myeloma | | | | |
CA204-219, NCT06163040: A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan |
|
|
| Completed | N/A | 7 | RoW | Elotuzumab in combination with pomalidomide and dexamethasone, Elotuzumab in combination with lenalidomide and dexamethasone | Bristol-Myers Squibb | Relapsed or Refractory Multiple Myeloma | 03/25 | 03/25 | | |
